Final overall survival (OS) results of befotertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Lu, S. [1 ]
Zhang, Y. [2 ]
Zhang, G. [3 ]
Zhou, J. [4 ]
Cang, S. [5 ]
Cheng, Y. [6 ]
Wu, G. [7 ]
Cao, P. [8 ]
Lv, D. [9 ]
Jian, H. [10 ]
Chen, C. [11 ]
Jin, X. [12 ]
Tian, P. [13 ]
Wang, K. [14 ]
Jiang, G. [15 ]
Chen, G. [16 ]
Chen, Q. [17 ]
Zhao, H. [18 ]
Ding, C. [19 ]
Ding, L. [20 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Med, Shanghai Chest Hosp, Med Oncol Dept, Shanghai, Peoples R China
[2] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Thorac Oncol, Hangzhou, Peoples R China
[3] Zhengzhou Univ, Affiliated Hosp 1, Dept Resp Med, Zhengzhou, Peoples R China
[4] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Resp Dis,Thorac Dis Ctr, Hangzhou, Peoples R China
[5] Henan Prov Peoples Hosp, Oncol, Zhengzhou, Henan, Peoples R China
[6] Jilin Canc Hosp, Med Oncol, Changchun, Jilin, Peoples R China
[7] Huazhong Univ Sci & Technol, Ctr Canc, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[8] Cent South Univ, Xiangya Hosp 3, Oncol, Changsha, Peoples R China
[9] Taizhou Hosp Zhejiang Prov, Dept Resp Med, Taizhou, Peoples R China
[10] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Med Oncol, Shanghai, Peoples R China
[11] Wenzhou Med Univ, Nanbaixiang Site, Affiliated Hosp 1, Dept Resp Med, Wenzhou, Peoples R China
[12] Ningxia Med Univ, Gen Hosp, Med Oncol Dept, Yinchuan, Ningxia, Peoples R China
[13] Sichuan Univ, West China Hosp, West China Sch Med, Dept Resp & Crit Care Med, Chengdu, Peoples R China
[14] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Resp Med, East Gate 1, Hangzhou, Peoples R China
[15] Dongguan Peoples Hosp, Dept Med Oncol, Dongguan, Peoples R China
[16] Harbin Med Univ, Canc Hosp, Dept Resp Med, Harbin, Peoples R China
[17] Fuzhou Pulom Hosp Fujian, Oncol, Fuzhou, Peoples R China
[18] Anhui Med Univ, Affiliated Hosp 2, Dept Resp & Crit Care Med, Hefei, Peoples R China
[19] Hebei Med Univ North Gate, Hosp 4, Dept Resp Med, Shijiazhuang, Hebei, Peoples R China
[20] Betta Pharmaceut Co Ltd, Hangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.565
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA9
引用
收藏
页码：S1654 / S1654
页数：1
相关论文
共 50 条
  • [1] Final results of APOLLO study: Overall survival (OS) of aumolertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Lu, S.
    Wang, Q.
    Zhang, G.
    Dong, X.
    Yang, C-T.
    Song, Y.
    Chang, G-C.
    Lu, Y.
    Pan, H.
    Chiu, C-H.
    Wang, Z.
    Feng, J.
    Zhou, J.
    Xu, X.
    Guo, R.
    Chen, J.
    Yang, H.
    Chen, Y.
    Yu, Z.
    Shiah, H-S.
    ANNALS OF ONCOLOGY, 2021, 32 : S962 - S962
  • [2] Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial
    Lu, Shun
    Zhang, Yiping
    Zhang, Guojun
    Zhou, Jianying
    Cang, Shundong
    Cheng, Ying
    Wu, Gang
    Cao, Peiguo
    Lv, Dongqing
    Jian, Hong
    Jin, Xiangming
    Chen, Chengshui
    Tian, Panwen
    Wang, Kai
    Jiang, Guanming
    Chen, Gongyan
    Chen, Qun
    Zhao, Hui
    Ding, Cuimin
    Guo, Renhua
    Sun, Guoping
    Wang, Bin
    Jiang, Liyan
    Liu, Zhe
    Fang, Jian
    Yang, Junquan
    Zhuang, Wu
    Liu, Yunpeng
    Zhang, Jian
    Pan, Yueyin
    Chen, Jun
    Yu, Qitao
    Zhao, Min
    Cui, Jiuwei
    Li, Dianming
    Yi, Tienan
    Yu, Zhuang
    Yang, Yan
    Zhang, Yan
    Zhi, Xiuyi
    Huang, Yunchao
    Wu, Rong
    Chen, Liangan
    Zang, Aimin
    Cao, Lejie
    Li, Qingshan
    Li, Xiaoling
    Song, Yong
    Wang, Donglin
    Zhang, Shucai
    LUNG CANCER, 2024, 195
  • [3] Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies
    Mitsudomi, T.
    Ahn, M-J.
    Bazhenova, L.
    Blackhall, F.
    Hida, T.
    Majem Tarruella, M.
    Vowler, S. L.
    Laus, G.
    Janne, P. A.
    Yang, J. C-H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer
    Joan Rou-En Choo
    Chee-Seng Tan
    Ross A. Soo
    Targeted Oncology, 2018, 13 : 141 - 156
  • [5] Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer
    Choo, Joan Rou-En
    Tan, Chee-Seng
    Soo, Ross A.
    TARGETED ONCOLOGY, 2018, 13 (02) : 141 - 156
  • [6] The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib
    Buder, Anna
    Hochmair, Maximilian J.
    Filipits, Martin
    TARGETED ONCOLOGY, 2021, 16 (01) : 77 - 84
  • [7] The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib
    Anna Buder
    Maximilian J. Hochmair
    Martin Filipits
    Targeted Oncology, 2021, 16 : 77 - 84
  • [8] AURA17 study of osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC): Updated phase II results including overall survival (OS)
    Zhou, C.
    Wang, M.
    Cheng, Y.
    Chen, Y.
    Zhao, Y.
    Shi, Y-K.
    Ahn, M-J.
    Lu, Y.
    Shi, M.
    Han, J-Y.
    Kim, S-W.
    Zhang, H-L.
    Chen, G.
    Li, H.
    Wang, J.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer
    Lamb, Yvette N.
    Scott, Lesley J.
    TARGETED ONCOLOGY, 2017, 12 (04) : 555 - 562
  • [10] Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer
    Yvette N. Lamb
    Lesley J. Scott
    Targeted Oncology, 2017, 12 : 555 - 562
12345